<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> is a systemic <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> associated with <z:mp ids='MP_0005048'>thrombosis</z:mp> and recurrent fetal loss in the setting of detectable antiphospholipid (aPL) antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>The major antigenic target has been identifed as β2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (β2GPI), which mediates binding of aPL antibodies to target cells including endothelial cells, monocytes, platelets and trophoblasts, leading to prothrombotic and proinfammatory changes that ultimately result in <z:mp ids='MP_0005048'>thrombosis</z:mp> and fetal loss </plain></SENT>
<SENT sid="2" pm="."><plain>This article summarizes recent insights into the role of β2GPI in <z:mpath ids='MPATH_458'>normal</z:mpath> hemostasis, interactions between aPL antibodies, β2GPI and cell-surface molecules, molecular prothrombotic and proinfammatory changes induced by aPL antibodies and pathogenic changes leading to fetal loss in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>New directions in therapy using these insights are examined </plain></SENT>
</text></document>